blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1478345

EP1478345 - NOVEL PHARMACEUTICAL DOSAGE FORMS AND METHOD FOR PRODUCING SAME [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  20.01.2012
Database last updated on 15.06.2024
Most recent event   Tooltip20.01.2012Application deemed to be withdrawnpublished on 22.02.2012  [2012/08]
Applicant(s)For all designated states
GlaxoSmithKline LLC
One Franklin Plaza
200 North 16th Street
Philadelphia, PA 19102 / US
[N/P]
Former [2010/09]For all designated states
GlaxoSmithKline LLC
One Franklin Plaza 200 North 16th Street
Philadelphia, PA 19102 / US
Former [2004/48]For all designated states
SMITHKLINE BEECHAM CORPORATION
One Franklin Plaza, P.O. Box 7929
Philadelphia, Pennsylvania 19101 / US
Inventor(s)01 / CLARKE, Allan, J.
1250 South Collegeville Road
Collegeville, PA 19426 / US
 [2004/48]
Representative(s)Walker, Ralph Francis
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
[N/P]
Former [2004/48]Walker, Ralph Francis, Dr.
GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Application number, filing date03703679.503.01.2003
[2004/48]
WO2003US00099
Priority number, dateUS20020345526P03.01.2002         Original published format: US 345526 P
[2004/48]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO03057197
Date:17.07.2003
Language:EN
[2003/29]
Type: A1 Application with search report 
No.:EP1478345
Date:24.11.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 17.07.2003 takes the place of the publication of the European patent application.
[2004/48]
Search report(s)International search report - published on:US17.07.2003
(Supplementary) European search report - dispatched on:EP20.10.2010
ClassificationIPC:A61K9/20
[2004/48]
CPC:
A61J3/10 (EP,US); A61K9/2095 (EP,US); A61J2200/20 (EP,US);
A61K9/0056 (EP,US); A61K9/0065 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SI,   SK,   TR [2004/48]
Extension statesALNot yet paid
LT26.07.2004
LV26.07.2004
MKNot yet paid
RO26.07.2004
TitleGerman:NEUE PHARMAZEUTISCHE DOSIERFORMEN UND VERFAHREN ZU IHRER HERSTELLUNG[2004/48]
English:NOVEL PHARMACEUTICAL DOSAGE FORMS AND METHOD FOR PRODUCING SAME[2004/48]
French:NOUVELLES FORMES POSOLOGIQUES PHARMACEUTIQUES ET PROCEDE DE PRODUCTION DE CES FORMES POSOLOGIQUES[2004/48]
Entry into regional phase26.07.2004National basic fee paid 
26.07.2004Search fee paid 
26.07.2004Designation fee(s) paid 
26.07.2004Examination fee paid 
Examination procedure24.07.2003Request for preliminary examination filed
International Preliminary Examining Authority: US
26.07.2004Amendment by applicant (claims and/or description)
26.07.2004Examination requested  [2004/48]
30.03.2011Despatch of a communication from the examining division (Time limit: M04)
02.08.2011Application deemed to be withdrawn, date of legal effect  [2012/08]
13.09.2011Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2012/08]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  30.03.2011
Fees paidRenewal fee
07.01.2005Renewal fee patent year 03
09.01.2006Renewal fee patent year 04
05.01.2007Renewal fee patent year 05
08.01.2008Renewal fee patent year 06
07.01.2009Renewal fee patent year 07
07.01.2010Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.01.201109   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]EP0240904  (BASF AG [DE]) [Y] 1-47 * page 2, line 32 - line 45 * * page 5, line 9 - line 11 * * example - * * claim - *;
 [XDI]EP0717988  (NIPPON SHINYAKU CO LTD [JP]) [XD] 1,2,5,6,8,9,11-16,18,19,22,23,25,26,29-32,34,36-38 * page 2, line 51 - page 3, line 5 * * page 5, line 34 - line 43 * * page 6, line 55 - page 7, line 31 * * example - * * claim - * [I] 1-38;
 [I]WO9906038  (BASF AG [DE], et al) [I] 1-18 * page 2, line 5 - line 42 * * page 4, line 14 - line 29 * * example - ** claim - *;
 [XDYI]US6150424  (BREITENBACH JOERG [DE], et al) [XD] 1,2,13-16,18 * column 1, line 26 - line 37 * * column 2, line 58 - column 3, line 25 * * column 3, line 26 - line 56 * * column 4, line 18 - column 6, line 28 * * example - * * claim - * [Y] 1-47 [I] 1-18
International search[X]US5766623  (AYRES JAMES W [US], et al);
 [Y]US5034171  (KICZEK EDWARD F [US], et al)
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.